Literature DB >> 11861316

Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites.

Marta López-Parra1, Joan Clària, Anna Planagumà, Esther Titos, Jaime L Masferrer, B Mark Woerner, Alane T Koki, Wladimiro Jiménez, Rosario Altuna, Vicente Arroyo, Francisca Rivera, Joan Rodés.   

Abstract

1. The maintenance of renal function in decompensated cirrhosis is highly dependent on prostaglandins (PGs). Since PG synthesis is mediated by cyclooxygenase-1 and -2 (COX-1 and COX-2), the present study was designed to examine which COX isoform is involved in this phenomenon. 2. Renal COX-1 and COX-2 protein expression and distribution were analysed by Western blot and immunohistochemistry in nine rats with carbon tetrachloride-induced cirrhosis and ascites and 10 control animals. The effects of placebo and selective COX-1 (SC-560) and COX-2 (celecoxib) inhibitors on urine flow (V), urinary excretion of sodium (U(Na)V) and PGE(2) (U(PGE2)V), glomerular filtration rate (GFR), renal plasma flow (RPF), the diuretic and natriuretic responses to furosemide and renal water metabolism were assessed in 88 rats with cirrhosis and ascites. 3. COX-1 protein levels were found to be unchanged in kidneys from cirrhotic rats. In contrast, these animals showed enhanced renal COX-2 protein expression which was focally increased in the corticomedullary region. Although U(PGE2)V was equally reduced by SC-560 and celecoxib, only SC-560 produced a significant decrease in U(Na)V, GFR and RPF and a pronounced impairment in the diuretic and natriuretic responses to furosemide in rats with cirrhosis and ascites. Neither SC-560 nor celecoxib affected renal water metabolism in cirrhotic rats. 4. These results indicate that despite abundant renal COX-2 protein expression, the maintenance of renal function in cirrhotic rats is mainly dependent on COX-1-derived prostaglandins.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861316      PMCID: PMC1573194          DOI: 10.1038/sj.bjp.0704528

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  40 in total

1.  Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells.

Authors:  C P Vio; C Cespedes; P Gallardo; J L Masferrer
Journal:  Hypertension       Date:  1997-09       Impact factor: 10.190

Review 2.  Prostaglandin synthase 2.

Authors:  H R Herschman
Journal:  Biochim Biophys Acta       Date:  1996-01-05

3.  Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues.

Authors:  G P O'Neill; A W Ford-Hutchinson
Journal:  FEBS Lett       Date:  1993-09-13       Impact factor: 4.124

4.  Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction.

Authors:  R C Harris; J A McKanna; Y Akai; H R Jacobson; R N Dubois; M D Breyer
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

5.  Differential regulation of renal cyclooxygenase mRNA by dietary salt intake.

Authors:  B L Jensen; A Kurtz
Journal:  Kidney Int       Date:  1997-11       Impact factor: 10.612

6.  High-performance liquid chromatography of the renal blood flow marker p-aminohippuric acid (PAH) and its metabolite N-acetyl PAH improves PAH clearance measurements.

Authors:  L A Decosterd; A Karagiannis; J M Roulet; N Bélaz; M Appenzeller; T Buclin; P Vogel; J Biollaz
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1997-12-05

7.  Regulation of cyclooxygenase expression in the kidney by dietary salt intake.

Authors:  T Yang; I Singh; H Pham; D Sun; A Smart; J B Schnermann; J P Briggs
Journal:  Am J Physiol       Date:  1998-03

8.  Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain.

Authors:  K Seibert; Y Zhang; K Leahy; S Hauser; J Masferrer; W Perkins; L Lee; P Isakson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

9.  Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity.

Authors:  K N Khan; C M Venturini; R T Bunch; J A Brassard; A T Koki; D L Morris; B F Trump; T J Maziasz; C L Alden
Journal:  Toxicol Pathol       Date:  1998 Sep-Oct       Impact factor: 1.902

10.  Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis.

Authors:  J Ros; J Clària; W Jiménez; M Bosch-Marcé; P Angeli; V Arroyo; F Rivera; J Rodés
Journal:  Hepatology       Date:  1995-09       Impact factor: 17.425

View more
  8 in total

1.  The oxidative stress mediator 4-hydroxynonenal is an intracellular agonist of the nuclear receptor peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta).

Authors:  Jeffrey D Coleman; K Sandeep Prabhu; Jerry T Thompson; P Sreenivasula Reddy; Jeffrey M Peters; Blake R Peterson; C Channa Reddy; John P Vanden Heuvel
Journal:  Free Radic Biol Med       Date:  2007-01-08       Impact factor: 7.376

Review 2.  Does cyclooxygenase-2 affect blood pressure?

Authors:  Hui-Fang Cheng; Raymond C Harris
Journal:  Curr Hypertens Rep       Date:  2003-02       Impact factor: 5.369

3.  Use of over-the-counter analgesics in patients with chronic liver disease: physicians' recommendations.

Authors:  Simona Rossi; David N Assis; Monica Awsare; Mark Brunner; Kevin Skole; Jitha Rai; Jocelyn Andrel; Steven K Herrine; Rajender K Reddy; Victor J Navarro
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

4.  The changes in renal function after a single dose of intravenous furosemide in patients with compensated liver cirrhosis.

Authors:  Nimer Assy; Mohib Kayal; Yoram Mejirisky; Miguel Gorenberg; Osamah Hussein; Sorina Schlesinger
Journal:  BMC Gastroenterol       Date:  2006-11-29       Impact factor: 3.067

Review 5.  The therapeutic use of analgesics in patients with liver cirrhosis: a literature review and evidence-based recommendations.

Authors:  Farnad Imani; Mahsa Motavaf; Saeid Safari; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2014-10-11       Impact factor: 0.660

Review 6.  Cyclo-Oxygenase (COX) Inhibitors and Cardiovascular Risk: Are Non-Steroidal Anti-Inflammatory Drugs Really Anti-Inflammatory?

Authors:  Shanzana Khan; Karen L Andrews; Jaye P F Chin-Dusting
Journal:  Int J Mol Sci       Date:  2019-08-30       Impact factor: 5.923

Review 7.  Nonsteroidal Anti-Inflammatory Drugs and the Kidney.

Authors:  Walter H Hörl
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-21

Review 8.  Different Chemical Structures and Physiological/Pathological Roles of Cyclooxygenases.

Authors:  Yalcin Faki; Ayse Er
Journal:  Rambam Maimonides Med J       Date:  2021-01-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.